checkpoint kinase inhibitors (Johnson & Johnson)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Namecheckpoint kinase inhibitors (Johnson & Johnson)
Drug Alias Name2-arylbenzimidazoles (J&JPRD)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCheckpoint kinase 2 inhibitors
TargetsCheckpoint kinase 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJohnson & Johnson Pharmaceutical Research & Development LLC
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A